[JPM 2026] Hugel Targets 900 Billion Won in Sales by 2028...U.S. to Account for 30%

Appeared on the Asia-Pacific Track Stage at JP Morgan Healthcare Conference on January 15

Hugel, a company specializing in medical aesthetics, has announced its plan to achieve annual sales of 900 billion won by 2028, with 30% of that revenue coming from the U.S. market.

Carrie Strom, Global CEO of Hugel, is speaking at the JP Morgan Healthcare Conference held on the 15th (local time) at the Westin St. Francis Hotel in San Francisco, California, USA. Hugel

On January 15 (local time), Carrie Strom, Global CEO of Hugel, presented this plan during the Asia-Pacific track at the JP Morgan Healthcare Conference held at the Westin St. Francis Hotel in San Francisco, California. She stated, "Hugel's vision is to become a leading global medical company in the future."

Entering its second year in the U.S. market, Hugel aims to establish a successful business foothold in the United States by introducing a hybrid sales model that combines direct sales and partnerships starting this year. Building on this foundation, the company aspires to become a global leader in medical aesthetics.

After obtaining approval from the U.S. Food and Drug Administration (FDA) in 2024, Hugel began full-scale sales in the U.S. market in 2025 through its local distribution partner, Benev. This year, the company will implement a 'hybrid sales' strategy, combining distribution through existing partners with direct sales. The strategy is to significantly enhance profitability and drive stable revenue growth and market share expansion.

Hugel aims to increase its U.S. market share to 10% by 2028 and to 14% by 2030. At the same time, the company plans to maintain its EBITDA margin at 50% as sales grow.

Hugel also plans to focus on expanding its product portfolio to create synergy with its existing flagship products, such as toxins and HA fillers. In particular, the company will pursue strategic business development through license-in agreements and co-promotion, respond to market demand centered on skin boosters, and build an aesthetic lineup optimized for the global market.

Jang Doohyun, CEO of Hugel, commented on the company's profitability strategy amid intensifying competition, saying, "Competing solely on toxin prices is a game of chicken. Ultimately, we are developing a structure that strengthens both clinic and our own profitability by offering packages that combine toxins, fillers, and boosters."